ATELVIA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ATELVIA (ATELVIA).
Risedronate (the active ingredient in ATELVIA) inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite in bone and inhibiting the mevalonate pathway, which prevents farnesyl pyrophosphate synthase activity, leading to disruption of osteoclast function and induction of apoptosis.
| Metabolism | Risedronate is not metabolized and is excreted unchanged primarily by the kidneys (<5% metabolized). No cytochrome P450 enzymes involved. |
| Excretion | Approximately 50% of absorbed dose excreted renally unchanged; remainder eliminated via biliary/fecal routes. Renal clearance correlates with creatinine clearance. |
| Half-life | Terminal elimination half-life is approximately 10 days due to prolonged bone binding and slow release; clinical suppression of bone resorption persists for weeks after discontinuation. |
| Protein binding | Approximately 99% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Mean Vd is 6.2 L/kg (range 4-10 L/kg), indicating extensive distribution into bone and soft tissues. |
| Bioavailability | Oral bioavailability is approximately 0.7% (range 0.5-1.0%) under fasting conditions; food and calcium-containing beverages significantly reduce absorption. |
| Onset of Action | Oral: Onset within 1 month; peak effect on bone turnover markers at 3-6 months. |
| Duration of Action | Duration of effect on bone resorption persists for weeks to months after treatment cessation due to binding to hydroxyapatite; clinical dosing interval is weekly. |
| Molecular Weight | 325.12 Da (as alendronate monosodium salt) |
35 mg orally once weekly on the same day each week, taken with at least 240 mL of plain water at least 30 minutes before the first food, beverage, or medication of the day. Do not crush, chew, or suck tablets.
| Dosage form | TABLET, DELAYED RELEASE |
| Renal impairment | Contraindicated in patients with CrCl <15 mL/min. No dose adjustment required for CrCl ≥15 mL/min. For CrCl 15-30 mL/min, use with caution due to limited data. |
| Liver impairment | No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe hepatic impairment (Child-Pugh C); use caution. |
| Pediatric use | Not approved for use in pediatric patients; safety and efficacy not established in children. |
| Geriatric use | No specific dose adjustment required. Consider potential renal impairment (assess CrCl) and increased risk of gastrointestinal adverse effects. Ensure adequate calcium and vitamin D intake. |
| 1st trimester | Data are limited; animal studies show adverse effects but human data insufficient to define risk. Use only if clearly needed. |
| 2nd trimester | Avoid due to potential fetal harm; no well-controlled studies. |
| 3rd trimester | Avoid; may cause fetal harm based on animal data and mechanism of action. |
Clinical note
Comprehensive clinical and safety monograph for ATELVIA (ATELVIA).
| Placental transfer | Atelvia (alendronate sodium) is a bisphosphonate; placental transfer has been demonstrated in animal studies. In humans, data are limited but suggest transfer likely. |
| Breastfeeding | It is not known whether atelvia is excreted in human milk. Because many drugs are excreted in milk and because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
Hypersensitivity to any component of this productHypocalcemiaInability to stand or sit upright for at least 30 minutesEsophageal abnormalities that delay esophageal emptying (e.g., stricture or achalasia)
| Precautions | Hypocalcemia must be corrected before therapy initiation, Severe renal impairment (CrCl <30 mL/min): not recommended, Osteonecrosis of the jaw (ONJ) with invasive dental procedures, Atypical femur fractures with long-term use, Upper gastrointestinal adverse events (e.g., esophagitis, ulcers) if taken incorrectly, Hypersensitivity reactions including angioedema |
| Food/Dietary | Food, beverages (except plain water), and calcium supplements reduce absorption. Avoid any food or drink for at least 30 minutes after dosing. Do not take with mineral water, coffee, tea, juice, or dairy products. Calcium, iron, magnesium, or aluminum-containing antacids should be taken at a different time of day. |
Loading safety data…
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | Category C: In animal studies, bisphosphonates cause fetal skeletal abnormalities at high doses. During first trimester, theoretical risk of skeletal formation interference. Second/third trimester: Potential for maternal hypocalcemia affecting fetal bone development. No adequate human studies. Risk cannot be excluded. |
| Fetal Monitoring | Monitor serum calcium, phosphate, and magnesium levels. Assess renal function (BUN, creatinine). During pregnancy, consider fetal ultrasound for skeletal development if exposure occurs. Monitor for maternal hypocalcemia symptoms. |
| Fertility Effects | No known direct effects on fertility in humans. In animal studies, no impairment of fertility observed at doses up to 0.5 mg/kg/day. Theoretical risk from altered bone metabolism, but clinical significance unknown. |
| Clinical Pearls | ATELVIA (risedronate) is a bisphosphonate for osteoporosis. Must be taken on an empty stomach with plain water only, at least 30 minutes before first food, drink, or other medication. Avoid in severe renal impairment (CrCl <30 mL/min). Monitor for hypocalcemia before initiation. Advise patients to remain upright for 30 minutes post-dose to reduce esophageal irritation. |
| Patient Advice | Take ATELVIA first thing in the morning, at least 30 minutes before any food, drink, or other medications. · Swallow the tablet whole with a full glass (6-8 oz) of plain water only; do not use mineral water, coffee, tea, or juice. · Do not chew, crush, or suck the tablet; remain upright (sitting or standing) for at least 30 minutes after taking. · If you miss a dose, skip it and take the next dose the following morning; do not take two doses on the same day. · Report symptoms of esophageal irritation such as difficulty or pain with swallowing, chest pain, or heartburn. · Ensure adequate intake of calcium and vitamin D as directed by your healthcare provider. |